Innovations and strategies for the development of anticancer

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 603-614

  Chamberlain, Ronald S ^a,b   Kaufman, Howard ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer treatment; Cancer vaccines; Gene therapy; Tumour antigens; Vaccinia virus

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 0034189097     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.603     Document Type: Article

References (103)

1. JENNERE: In: An Inquiry into the Causes and Effects of the Variolae Vacciniae, a Disease Discovered in some of the Western Counties of England, Particularly near Gloucestershire, and known by the Käme of the Cow Pox. Sampson & Low, London, UK «1798):213-240.
2. COLEY WB: ne Treatment of Inoperable Sarcoma by Bacterial Toxin (the Mixed Toxins of the Streptococcus Erysipelas and the Bacillus Prodigious). John Bale, Sons & Danielsson Ltd., London, UK (1909).
3. LINEMAN DC, GOEDEGEBUURE PS, EBERLEIN, TJ: Vaccine therapy for cancer. Ann. Surg. Oncol. (1996) 3:219-228.
4. GROSS L: Intradermal immunization of C3H mice against a sarcoma that originated in animal of the same line. Cancer Res. (1943) 3:326-322.
5. PREHN RT, MAIN MJ: Immunity to methylchloranthrene-induccd sarcomas. J. Natl. Cancer Inst. (1957) 18:769-778.
6. GOEDEGEBUURE PS, BERLEIN TJ: Vaccine trials for the clinician: prospects for viral and non-viral vectors. Oncologist (1997) 2:300-308.
7. OSANATO S: Vaccine trials for the clinician: prospects for tumor antigens. Oncologist (1997) 2:284-299.
8. VAN DER BRUGGEN P, TRAVERSARIC, CHOMEZ P étal.: A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science (1991) 254:1643-1647.
9. VAN DER BRUGGEN P, SZIKORA J-P, BOEL P et al.: Autologous cytolytic T-lymphocyte recognizes a MAGE-1 nonapcptidc on melanomas expressing HIA-cwl601. Eur.J. Immwwl. (1994) 21:34-40.
10. GREENBERG PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immimol. (1991) 49:281-355.
11. YEWDELL JW, BENN1NK JR: CeU biology of antigen processing and presentation to major histocompatability complex class I molecules-restricted T lymphocytes. Adv. Immimol. (1992) 52:1-123.
12. ACCOLLA RS, ADORINI L, SANTORIS S, SINIGAGLIA F, GUARDIOLA J: MHC: orchestrating the immune response. Immunol. Today(199>) 16:8-11.
13. TOPALIAN SL, SOLOMON D, ROSENBERG SA: Tumorspecific cytolysis by lymphocytes infiltrating human melanomas.J. Immunol. (1989) 142:3714-3725.
14. ROSENBERG SA, PACKARD BS, AEBERSOLD PM etal.: Use of tumor infiltrating lymphocytes and intcrlcukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. (1988) 319:1676-1680.
15. KAWAKAMI Y, ELIYAHU S, DELGADO CH et ah Cloning of the gene encoding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Nall.Acad. Sci. USA (1994) 91:3515-3519-
16. HAMMARSTROM S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Blol. (1999) 9:67-81.
17. ROBB1NS PF, EL-GAM1L M, LI YF: A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. (1996) 183:1185-1192.
18. + T cell lines from patients immunized with ras oncogene-derived peptldes reflecting codon 12 mutations. Cell Immunol. (1997) 15:137-151.
19. FERRONE S, MARINCOLA FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today (1995) 16:487-494.
20. RESTIFO NP, BACIK I, IRVINE KR et al.: Antigen processing in vivo and the dictation of primary CTL responses. J Immunol. (1995) 154:4414-41422.
21. FEARON ER, PARDOLL DM, ITAYA T et al.: Interleukin-2 production by tumor cells bypasses T-hclpcr function in the generation of an antitumor response. Cell (1990) 60:397-403.
22. BLANKENSTEIN T, QIN Z, UBERLA K et al.-. Tumor suppression after tumor cell-targeted tumor necrosis factor y. / Exp. Med. (1991) 173:1047-1052.
23. DRANOFF G, JAFFEE EM, LAZENBY AJ: Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543.
24. HARRIS JE, RYAN L, HOOVER HC JR et ah. Adjuvant active specific immunothcrapy for Stage n and in colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. (2000) 18:148-157.
25. ARIENTIF, BELLI F, NAPOLITANO F étal.: Vaccination of melanoma patients with, interleukin 4 gene-transduced allogeneic melanoma cells. Human Gene Tber. (1999) 10:2907-2916.
26. LI Q, NORMOLLE DP, SAYRE DM et al.: Immunological effects of BCG as an adjuvant in autologous tumor vaccines. Clin. Immunol. (2000) 94:64-72.
27. MITCHELL MS, KAN-MITCHELL J, KEMPF RA, HAREL W, SHAU HY, LIND S: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysatcs and a novel adjuvant. Cancer Res. (1998) 48:5883-5893.
28. VERMOKEN JB, CLAESSEN AM, VAN TINTEREN H et al.: Active-specific immunothcrapy for Stage II and Stage III human colon cancer: a randomised trial. Lancet (1999) 353:345-350.
29. BERD D, MAGUIRE HC, JR., MASTRANGELO MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of métastases after treatment with a melanoma cell vaccine preceded by cyclophosphamldc. Cancer Res. (1986) 46:2572-2577.
30. BERD D, MAGUIRE HC, JR., MCCUE P, MASTRANGELO MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologie results in 64 patients./ Clin. Oncol. (1990) 8:1858-1867.
31. BERD D, MURPHY G, MAGUIRE HC, JR., MASTRANGELO MJ: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma métastases. Cancer Res. (1991) 51:2731-2734.
32. BERD D, MAGUIRE HC, JR., MASTRANGELO MJ: Treatment of human melanoma with a haptenmodifled autologous vaccine. Ann. NY Acad. Sci. (1993) 690:147-152.
33. BERD D, MAGUIRE HC, JR., MASTRANGELO MJ, MURPHY G : Activation markers on T cells infiltrating melanoma métastases after therapy with dinitrophenylconjugated vaccine. Cancer Immunol. Immunother (1994) 39:141-147.
34. MORTON DL, FOSHAG LJ, HOON DS et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216:463-482. [Published erratum appears in Ann. Surg. (1993) 217:309).
35. HSEUH EH, FAMATIGA E, GUPTA RK, QI K, MORTON DL: Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (Cancer Vax): correlation with survival Ann. Surg. Oncol. (1998) 5:595-602.
36. WALLACK MK, SIVANANDHAM M, BALCH CM et al.: A phase in randomized, double-blind multi-institutional trial of vaccinia melanoma oncotysates - active specific immunotherapy for patients with Stage II melanoma. Cancer (1995) 75:34-i2.
37. FLEXNER S: The results of the serum treatment in thirteen hundred cases of epidemic meningitis./ Exp. Meet. (1913) 17:553.
38. LIVINGSTON PO, DELEO AB, JONES M, OETTGEN HF, OLD LJ: Comparison of approaches for augmenting scrological responses to Mcth A antigen. Pretreatmcnt with cyclophosphamide is most effective.J. Immunol. (1983) 131:2601.
39. GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmettc-Guerin. Clin. Cancer Res. (1999) 5:1319-1323.
40. SLOVIN SF, RAGUPATHI G, ADLURIS étal.-. Carbohydrate vaccines in cancer: immunogcnicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA (1999) 96:5710-5715.
41. YAO TJ, MEYERS M, LIVINGSTON PO et al.: Immunization of melanoma patients with BEC2-keyboId limpet hemocyanin plus BCG interdermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin. Cancer Res. (1999) 5:77-81.
42. FOON KA, SEN G, HUTCHINS L et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. (1998) 4:1117-1124.
43. ESKOLA J, KAVRTY H, TAKUIA AK et al.: randomized prospective trials of a conjugate vaccine in the protection of infants and young children against invasive Haemopbilus inβuenzae type b disease. N. Engl.J. Med. (1990) 323:1381-1387.
44. HELLING F, SHANG Y, CALVES M, OETTGEN HF, LIVINGSTON PO: Increased immunogenecity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res. (1994) 54:197-203.
45. HELLING F, ZHANG A, SHANG A et al.: GM2-KLH conjugate vaccine: Increased immunogenecity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. (1995) 55:2783-2788.
46. LIVINGSTON PO, KAELIN K, PINSKY CM, OETTGEN HF, OLD LJ: The sérologie response of patients with Stage D melanoma to allogeneic melanoma cell vaccines. Cancer (1985) 56:2194-2200.
47. LIVINGSTON PO, NATOLI EJ, CALVES MJ, STUCKERT E, OETTGEN HF, OLD LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA (1987) 85:2911-2915.
48. LIVINGSTON PO, RITTER G, SRIVASTAVA P et ah. Characterization of IgG and Ig M antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res. (1989) 49:7045-7050.
49. RESSING ME, OFFRINGA R, TOES RE et al.: Inununotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotecbnology(.1996) 2:241-251.
50. CELIS E, SETTE A, GREY HM: Epitope selection and development of peptide based vaccines to treat cancer. Sem. Cancer Biol. (1995) 6:329-336.
51. URBAN JL, SCHREIBER H: Tumor antigens. Ann. Rev. Immunol (1992) 10:617-644.
52. BOON T, CEROTTINIJC, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. (1994) 12:337-365.
53. RAMMENSEE H-G, FRIEDE T, STEVANOVIC S: MHC ligands and peptide mollis: first listing. Immunogenettcs (1995) 41:178-228.
54. SETTE A, VIT1ELLO A, REHRMAN B et al.: The relationship between class I binding affinity and the immuno genecity of potential cytotoxic T cell epitopes. J. Immunol. (1994) 153:5586-5592.
55. KAWAKAMI Y, ELIYAHU S, SAKAGUCHI K et al.: Identification of the immunodominant pcptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.J. Exp. Med. (1994) 180:347-352.
56. MARCHAND M, WEYNANTS P, RANKIN E et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer(1995) 63:883.885.
57. JAEGER E, BERNHARD H, ROMERO P et al.: Generation of cytotoxic T-cell responses with synthetic melanomaassociated peptide« in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. / Cancer (1996) 66:162-169.
58. MAYORDOMO JL, ZORINA T, SORKUS WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour pcptides elicit protective and therapeutic antitumor immunity. Nature Med. (1995) 1:1297-1302.
59. YOUNG JW, INABA'K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity./ Exp. Med. (1996) 183:7-11.
60. ZHOU F, ROUSE BT, HUANG L: Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. (1992) 53:6287-6291.
61. + CTL in vivo with peptide vaccine constructs.J. Immunol. (1994) 152:549-555.
62. MARCHAND M, WEYNANTS P, RANKING E et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer (1995) 63:883-885.
63. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Mecl. (1998) 4:321-327.
64. GJERTSEN MK, BAKKA A, BREIVIK J et al.: Ex vivo ras peptlde vaccination in patients with advanced pancreatic cancer: results of a phase I/n study. Int.J. Cancer (1996) 65:450-453.
65. BLACHERE NE, SRIVASTAVA PK: Heat shock proteinbased cancer vaccines and related thoughts on immunogenecity of human tumors. Sem. Cancer Biol. (1995) 6:349-355.
66. SRIVASTAVA PK: Peptide-blnding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res. (1993) 62:153-177.
67. DAVIS HL, WHALEN RG, DEMENIEX BA: Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum. Gene Tber. (1993) 41:151-159.
68. CHEN CH, JI H, SUH KW et al: Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expresslng murinc tumor métastases In the liver and lungs. Gene Ther. (1999) 6:1972-1981.
69. FULLER DH, HAYNES JR. A qualitative progression in HIV type 1 glycoprotein 120-spccific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Human Retrofit. (1994) 10:1433-1441.
70. WANF B, UGEN EU, SRIKANTAN V et al: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1993) 90:4156-4160.
71. CONROY RM, LOBUGLIO AF, LOECHEL F et al.-. A careinocnibryonic antigen polynucleotlde vaccine has in vivo antitumor activity. Gene Tber. (1995) 2:59-65.
72. WANG B, MERVA M, DANG K, UGEN KE, WILLIAMS WV, WEINER DB. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Human Gene ner. (199.5) 6:407-418.
73. NABEL G, GORDON D, BISHOP DK et ah Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sel. USA (1996) 93:15388-15393.
74. IRVINE KR, RAO JB, ROSENBERG SA, RESITFO NP: Cytokinc enhancement of DNA Immunization leads to effective treatment of established pulmonary métastases. J.lmmunol (1996) 156:224-231.
75. ARITA I: Virological evidence for the success of the smallpox eradication programme. Nature (1979) 279:293.
76. MOSS B: Vaccinia virus: a tool for research and vaccine development. Science (1991) 252:l662-l667C.
77. CHAMBERLAIN RS, IRVINE KR, RESTIFO NP. The development of rccomblnant poxviruses for use as anticancer vaccines. In: TumorImmunotherapy. Liu S (Ed.), Academic Press, Orlando, USA (1998).
78. MCCABE BJ, IRVINE KR, NISHIMURA MI: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. (1995) 55:1741-1747.
79. KUNDIG TM, BACHMANN MF, LEFRANCOIS L, PUDDINGTON L, HENGARTNER H, ZINKERNAGEL RM: Non immunogenlc tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J. Immiinol. (1993) 150:4450-4456.
80. KANTOR J, ABRAMS S, IRVINE K, SNOY P, KAUFMAN H, SCHLOM J: Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann. NYAcad. Sci. (1993) 690:370-373.
81. ESTIN CD, STEVENSON U, KAHN M, HELLSTROM I, HELLSTROM KE: Transfected mouse melanoma lines that express various levels of human melanomaassociated antigen p97. / Natl. Cancer Inst. (1989) 81:445-448.
82. RONEN D, TEITZ Y, GOLDFINGER N, ROTTER V: Expression of wild-type and mutant p53 proteins by recombinant vaccinia virus. Nucleic Acid Res. (1992) 20:3435-3441.
83. LATHE R, KIENY MP, GERLINGER P et al.: Tumour prevention and rejection with recombinant vaccinia. Nature (.1987) 326:878-880.
84. BALLOUL JM, ACRES RB, GEIST M et al.: Recombinant MUC 1 vaccinia virus: a potential vector for Immunotherapy of breast cancer. CellMol.Biol. (1994) 40:49-59.
85. HAREUVENI M, WRESCHNE» D, KIENY MP: Vaccinia recombinants expressing secreted and transmembranc forms of breast cancer-associated epithelial tumor antigen (ETA). Vaccine (1991) 9:618-626.
86. WANG M, BRONTE V, CHEN PW et al.: Active immunotherapy of cancer with a non-replicating rccombinant fowlpox virus encoding a model tumor-associated antigen./ Immunol. (1995) 154:4685-4692.
87. CHAMBERLAIN RS, CARROLL MW, BRONTE V et al.: Co-stimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. (1996) 56:2832-2836.
88. OONEY EL, COLLIER AC, GREENBERG PD et al: Safety of and immunological response to a recombinant virus vaccine expressing HIV envelope glycoprotein. Lancet (199D 337:567-572.
89. GRAHAM BS, BELSHE RB, CLEMENTS ML et al.: Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gploO recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The Aids Vaccine Clinical Trials Network. / Infect. Dis. (1992) 166:244-252.
90. FULLER DH, HAYNES JR: A qualitative progression in HIV type 1 glycoprotein 120-spccific vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine (1993) 11:1154-1158.
91. HAMILTONJM, CHEN AP, NGUYEN B étal.-. Phaselstudy of recombinant vaccinia virus that expresses human carcinoembryonic antigen in adult patients with adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (1994) 13:295-
92. CONRY RM, KHAZAELI MB, SALEH MN et al: Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in mctastatlc adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. (1999) 5:2330-2337.
93. HODGE JW, SCHLOM J, DONOHUE SJ et al: A recombinant vaccinia virus expressing human prostatespecific antigen (PSA): safety and immunogenicity in a non-human primate. Int.J. Cancer (1995) 63:213-237.
94. KARR JF, KANTOR JA, HAND, PH EGGENSPERGER DL, SCHLOM J: The presence of prostate-specific antigenrelated genes hi primates and the expression of recombinant human prostate-specific antigen hi a transfectcd murine cell line. Cancer Res. (1995) 55:2455-2462.
95. STOVER CK, DE LA CRUZ VF, FUERST TR et al.: New use of BCG for recombinant vaccines. Nature (199D 351:456-460.
96. SCHAFER R, PORTNOY DA, BRASSELL SA, PATERSON Y: Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine./ Immunol (1992) 149:53-59.
97. PAN Z-K, IKONNOMIDIS G, LAZENBY A, PARDOLL D, PATERSON Y: A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor cell challenge and causes regression of established tumours. Nature Med. (1995) 1:471-480.
98. IRVINE KR, CHAMBERLAIN RS, SHULMAN EP, ROSENBERG SA, RESTIFO NP: Route of immunization and the therapeutic impact of recombinant anticancer vaccines./ Katl. Cancer Inst. (1997) 89:390-392.
99. RESTIFO NP, KAWAKAMI Y, MARINCOLA F et al.-. Molecular mechanisms used by tumors to escape immune recognition: immunogene therapy and the cell biology of major his tocompatibility complex class I./ Immunother. (1993) 14:182-190.
100. LOTZE MT: Cytokine gene therapy of cancer. Cancer J. Sci. Am. (1996) 2:63-72.
101. FYFE G, FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, LOUIE AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who , received high-dose recombinant interlcukin-21 therapy./ Clin. Oncol. (1995) 13:688-696.
102. MCELRATH MS: Selection of potent immunologie adjuvants for vaccine construction. Sem. Cancer Biol. (1995) 6:373-385.
103. IRVINE KR, CHAMBERLAIN RS, SHULMAN EP, SURMAN DR, ROSENBERG SA, RESTIFO NP: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors./ Ai?/J. Cancer Inst. (1997) 89:1595-1601.